| Item Type | Name |
|
Concept
|
Glomerular Filtration Rate
|
|
Academic Article
|
Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria.
|
|
Academic Article
|
Comparative effects of different antihypertensive treatments on progression of diabetic renal disease.
|
|
Academic Article
|
Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients.
|
|
Academic Article
|
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
|
|
Academic Article
|
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
|
|
Academic Article
|
Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors.
|
|
Academic Article
|
When to discontinue ACE inhibitors for nephropathy.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
|
|
Academic Article
|
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
|
|
Academic Article
|
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).
|
|
Academic Article
|
What have we learned from the current trials?
|
|
Academic Article
|
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
|
|
Academic Article
|
Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.
|
|
Academic Article
|
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.
|
|
Academic Article
|
ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
|
|
Academic Article
|
Cardiometabolic syndrome and chronic kidney disease: what is the link?
|
|
Academic Article
|
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented.
|
|
Academic Article
|
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented.
|
|
Academic Article
|
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
|
|
Academic Article
|
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented.
|
|
Academic Article
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
|
Academic Article
|
A role for calcium in radiocontrast-induced reductions in renal hemodynamics.
|
|
Academic Article
|
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Limitations of metformin use in patients with kidney disease: are they warranted?
|
|
Academic Article
|
Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease?
|
|
Academic Article
|
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies.
|
|
Academic Article
|
The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol.
|
|
Academic Article
|
Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk.
|
|
Academic Article
|
Assessment and management of vascular disease risk in patients with chronic kidney disease.
|
|
Academic Article
|
Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women.
|
|
Academic Article
|
Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial.
|
|
Academic Article
|
ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects.
|
|
Academic Article
|
Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals.
|
|
Academic Article
|
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).
|
|
Academic Article
|
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
|
|
Academic Article
|
Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease.
|
|
Academic Article
|
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Renal function and target organ damage in hypertension.
|
|
Academic Article
|
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.
|
|
Academic Article
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
|
Academic Article
|
Role for intrarenal adenosine in the renal hemodynamic response to contrast media.
|
|
Academic Article
|
Preservation of renal function: the spectrum of effects by calcium-channel blockers.
|
|
Academic Article
|
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
|
|
Academic Article
|
Level of kidney function determines cardiovascular fate after coronary bypass graft surgery.
|
|
Academic Article
|
Renin-angiotensin blockade and kidney disease.
|
|
Academic Article
|
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
|
|
Academic Article
|
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
|
|
Academic Article
|
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
|
|
Academic Article
|
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
|
|
Academic Article
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
|
Academic Article
|
Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly.
|
|
Academic Article
|
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
|
|
Academic Article
|
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
|
|
Academic Article
|
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Efficacy and safety of perindopril arginine + amlodipine in hypertension.
|
|
Academic Article
|
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
|
|
Academic Article
|
The Kidney in Hypertension.
|
|
Academic Article
|
Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease.
|
|
Academic Article
|
Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk.
|
|
Academic Article
|
Baseline characteristics and enrichment results from the SONAR trial.
|
|
Academic Article
|
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
|
|
Academic Article
|
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).
|
|
Academic Article
|
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
|
|
Academic Article
|
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.
|
|
Academic Article
|
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
|
|
Academic Article
|
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Major adverse renal events (MARE): a proposal to unify renal endpoints.
|
|
Academic Article
|
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
|
|
Academic Article
|
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
|
|
Academic Article
|
Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease.
|
|
Academic Article
|
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
|
|
Academic Article
|
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
|
|
Academic Article
|
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
|
|
Academic Article
|
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
|
|
Academic Article
|
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
|
|
Academic Article
|
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
|
|
Academic Article
|
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
|
|
Academic Article
|
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
|
|
Academic Article
|
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
|
|
Academic Article
|
Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm.
|
|
Academic Article
|
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
|
|
Academic Article
|
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
|
|
Academic Article
|
Kidney function assessment and endpoint ascertainment in clinical trials.
|
|
Academic Article
|
Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review.
|
|
Academic Article
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
|
|
Academic Article
|
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design.
|
|
Academic Article
|
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.
|
|
Academic Article
|
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
|
|
Academic Article
|
Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression.
|
|
Academic Article
|
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
|
|
Academic Article
|
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
|
|
Academic Article
|
Albuminuria and Heart Failure: JACC State-of-the-Art Review.
|
|
Academic Article
|
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
|
|
Academic Article
|
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
|
|
Academic Article
|
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
|